Cleared Traditional

K003959 - QUANTA LITE CENTROMERE (CENP-A & CENP-B...

K003959 is the FDA 510(k) clearance for QUANTA LITE CENTROMERE (CENP-A & CENP-B... by Inova Diagnostics, Inc.. It is a Class 2 Immunology device (product code LJM) cleared through the Traditional 510(k) pathway after a 32-day FDA review.

K003959 · Inova Diagnostics, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2001
Decision
32d
Days
Class 2
Risk

K003959 is an FDA 510(k) clearance for the QUANTA LITE CENTROMERE (CENP-A & CENP-B) ELISA. Classified as Antinuclear Antibody (enzyme-labeled), Antigen, Controls (product code LJM), Class II - Special Controls.

Submitted by Inova Diagnostics, Inc. (San Diego, US). The FDA issued a Cleared decision on January 22, 2001 after a review of 32 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Inova Diagnostics, Inc. devices

Submission Details

510(k) Number K003959 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 21, 2000
Decision Date January 22, 2001
Days to Decision 32 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
72d faster than avg
Panel avg: 104d · This submission: 32d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls

All 38
Devices cleared under the same product code (LJM) and FDA review panel - the closest regulatory comparables to K003959.
QUANTA FLASH CENTROMERE
K123880 · Inova Diagnostics, Inc. · Feb 2014
IMMULISA ANTINUCLEAR ANTIBODY SCREEN ELISA
K041102 · Immco Diagnostics, Inc. · Oct 2004
ANA EIA DIAGNOSTIC TEST KIT
K004019 · The Binding Site, Ltd. · Feb 2001
THE APTUS (AUTOMATED) APPLICATION OF THE TG IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000879 · Zeus Scientific, Inc. · May 2000
THE APTUS (AUTOMATED APPLICATION OF THE TPO IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000880 · Zeus Scientific, Inc. · May 2000
RELISA ANA SCREENING TEST SYSTEM, MODEL 7096-11
K992041 · Immuno Concepts, Inc. · Jul 1999